PNC-27 (10 mg Vial) Dosage Protocol
PNC-27 is a synthetic peptide combining the p53 MDM2-binding domain with a membrane-residence sequence, studied for selective induction of necrosis in cancer cells.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = 3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg (0.10 mg) | 3 units (0.03 mL) |
| Weeks 3–4 | 200 mcg (0.20 mg) | 6 units (0.06 mL) |
| Weeks 5–8 | 300 mcg (0.30 mg) | 9 units (0.09 mL) |
| Weeks 9–12 | 400 mcg (0.40 mg) | 12 units (0.12 mL) |
| Weeks 13–16 | 500 mcg (0.50 mg) | 15 units (0.15 mL) |
Frequency: Inject once daily subcutaneously. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Critical Note: No authoritative human dosing exists for PNC-27. The FDA warns that PNC-27 safety has not been established. Any dosing above a few hundred micrograms per day is purely speculative.
Reconstitution Steps
- Draw 3 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Calculated from the schedule above for a 10 mg vial reconstituted with 3 mL (one injection per day, two swabs per injection).
| Item | 8 weeks | 12 weeks | 16 weeks |
|---|---|---|---|
| Peptide vials (10 mg each) | 2 vials (12.6 mg total) | 3 vials (23.8 mg total) | 4 vials (37.8 mg total) |
| Insulin syringes (U-100) | 56 syringes | 84 syringes | 112 syringes |
| Bacteriostatic water (10 mL bottles) | 6 mL → 1 × 10 mL bottle | 9 mL → 1 × 10 mL bottle | 12 mL → 2 × 10 mL bottles |
| Alcohol swabs | 112 swabs → 2 × 100-count boxes | 168 swabs → 2 × 100-count boxes | 224 swabs → 3 × 100-count boxes |
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 30 days, protect from light |
Important Notes
How This Works
PNC-27 fuses the p53 N-terminal MDM2-binding region (residues 12-26) with the leader sequence of penetratin or other membrane-residence peptides. The result selectively binds HDM-2 expressed at the cancer-cell membrane (a tumor-specific phenomenon) and triggers necrosis without affecting normal cells lacking surface HDM-2.
Potential Benefits & Side Effects
Potential Benefits
- Cancer-cell-selective necrosis in preclinical models.
- Spares normal cells lacking surface HDM-2.
- Studied in multiple solid tumor models.
Side Effect Profile
- Limited human safety data.
- Investigational compound — research only.
Lifestyle Factors
- Use is research only; not a standalone treatment.
Injection Technique
- Research protocol dictates route.